Mohammad AskarPublic working copy · medical review pending

Preservatives in glaucoma · 179

Preservatives in glaucoma therapy

Control pressure while examining the ocular surface and the real treatment burden.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Preservative-free treatment can help selected patients, but symptom relief, pressure control and long-term surgical benefit are different outcomes.

Terminology and draft status

Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.

01Identify exposure before assigning blame

Benzalkonium chloride (BAK) is a quaternary ammonium preservative used in many multidose drops. Its antimicrobial detergent action can also affect epithelial membranes and the tear film; toxicity depends on concentration, frequency, duration, formulation and the individual surface. 1

Preservatives protect against contamination, but not every multidose system needs a chemical preservative: validated containers can maintain microbiological safety. The export also names cetrimide (its spelling Zitrimit remains unresolved), thiomersal, parabens, chlorhexidine and polymyxin B; their roles differ, and chlorhexidine or polymyxin used as active anti-infectives must not be treated as interchangeable excipients. 1

02Separate laboratory toxicity from clinical outcomes

The original threshold 0.005%, the range 0.005–0.02%, damage above 0.05% and animal exposure up to 1.0% are retained in the table as exposure examples. Without the exact model and exposure time they do not establish a universal human toxicity threshold or predict the effect of one prescribed drop. 1

The identified 2020 systematic review included 16 studies; 13 trials with 4201 participants contributed to IOP analysis over 15 days to 6 months. Pressure differences were small, while safety reporting was heterogeneous and bias often high or unclear. This does not prove identical anterior-chamber penetration, equal long-term safety or a universal advantage for every preservative-free preparation. 2

Separate laboratory toxicity from clinical outcomes
Original BAK exposureInterpretation
0.005–0.02%Common formulation range; tear-film/epithelial effects depend on model and exposure
>0.05%Original necrosis/cytotoxicity claim; no universal clinical threshold established here
Up to 1.0%Original animal anterior-segment/endothelial destruction; not routine human dose

03Examine tear film, epithelium and nerves

BAK exposure can disturb the lipid layer and epithelial integrity, with shorter tear break-up time (BUT), staining, goblet-cell loss and inflammatory changes. Schirmer testing estimates aqueous tear production; it is not a direct measurement of tear turnover. Meibomian gland dysfunction (MGD; original MDD) and the active drug may contribute independently. 1

Confocal nerve changes and reduced corneal sensitivity are possible findings, not proof that every symptom is neurotoxicity. The original cyclosporin A 0.05% twice daily for 6 months and nerve-regeneration claim lacks a verified study here; it is not a guaranteed restorative treatment or a general prescription. 1

MMP9 reflects inflammation but is not specific for preservative toxicity. The original 50% versus 17% positive-test comparison lacks a verified denominator and design. Hyperaemia alone does not prove inflammation: netarsudil-associated vasodilatation, allergy, infection and surface injury require different management; the export spelling Netasudil/Rocklander is unresolved product terminology. 1

04Interpret scarring and surgery evidence cautiously

Chronic conjunctival inflammation can involve lymphocytes, dendritic cells and fibroblasts and may contribute to scarring, including drug-associated pseudopemphigoid. Progressive cicatrisation needs assessment for other causes such as mucous-membrane pemphigoid; the appearance alone does not establish a drug cause. 1

The export cites Broadway and a primary filtration success of 90% without the exact study or endpoint. Conjunctival cell-profile associations are not randomised proof that BAK alone causes surgical failure; disease severity, treatment duration, multiple drugs and operative technique can confound comparisons. Preserve this concern when planning surgery, without promising a specific success gain after switching drops. 1

Experimental oxidative stress and apoptosis in trabecular cells motivate research. The original term inflammatory trabeculopathy does not establish that routine preserved treatment destroys pressure regulation in every patient; effective IOP lowering remains essential to protect vision. 1

05Ask how treatment is actually used

Adherence means taking treatment as agreed; persistence means continuing it over time. Original estimates of 70% with prostaglandins, adherence 89% versus 63% with surface symptoms and 33–39% persistence at 1 year have unverified populations and definitions. Symptoms matter, but affordability, dexterity, cognition, schedule and access also influence use. 1

Ask about burning, foreign-body sensation, fluctuating vision and self-discontinuation without blaming the patient. Observe instillation, review the number of drops and consider simpler or fixed-combination regimens if clinically appropriate, while checking pressure and tolerability. 1

06Choose a surface plan without losing pressure control

Assess symptoms, BUT, corneal/conjunctival staining, lids and meibomian function. A BUT <10 seconds is an original teaching threshold, not a diagnosis by itself; MMP9 can be supplementary and is not mandatory for every patient. The cited 2024 Delphi consensus is unidentified and cannot be called a verified guideline. 1

Review a possible switch to a suitable preservative-free pressure drug and preservative-free lubricants, with an agreed IOP check. Treat lid disease with appropriate warming and hygiene; doxycycline requires selected indications and contraindication review. A change is individual, not an automatic immediate switch for every red eye. 1

Selected anti-inflammatory treatment may include short monitored topical steroids or cyclosporin after excluding infection; steroids can raise IOP and require caution in glaucoma. SLT or surgery may reduce drop burden in eligible eyes, but neither is indicated solely by an unconfirmed toxicity label. Preservative-free treatment is a useful option, not a universally established gold standard or a reason to abandon effective therapy. 1

Choose a surface plan without losing pressure control
TopicMechanism hypothesisFindingManagement and limit
BAK surface effectDetergent/membrane disturbanceShort BUT and stainingReview exposure and suitable PF option; preserve IOP control
Epithelial cellsApoptosis/goblet-cell lossDryness and mucin disturbancePF lubricants and cause-specific care, not proof from symptoms alone
InflammationCytokines/MMP9Follicular or inflammatory surface signsExclude infection/allergy; selected monitored anti-inflammatory care
Nerve changesPossible subepithelial injuryReduced sensitivityEvaluate other causes; no guaranteed CsA nerve restoration
FibrosisInflammatory/fibroblast responseScarring and surgical concernPlan surface optimisation; no proven universal surgical success gain
What are the main learning points?

Preservative-free treatment can help selected patients, but symptom relief, pressure control and long-term surgical benefit are different outcomes.

When is assessment urgent?

Sudden visual loss, severe pain, corneal ulceration or marked pressure elevation requires urgent assessment. Do not stop pressure-lowering treatment without an agreed alternative.

References and access status

  1. 1
    Immutable original export; preservative lecture; named quotations/appointments unverified

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Hedengran et al. 2020 systematic review; PMID 32051133

    Selected indexed abstract methods/results read 16 November 2026; 16 studies, IOP analysis 13/4201, short heterogeneous follow-up and high/unclear bias. Full report/supplement unread; no penetration equivalence established.